SCH772984

目录号:S7101

SCH772984 Chemical Structure

Molecular Weight(MW): 587.67

SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。

规格 价格 库存 购买数量  
RMB 2210.07 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • 293T cells were transfected with Flag-WT-FBW7. Thirty hours post transfection, cells were pretreated with MG132 and various MEK/ERK inhibitors overnight before harvesting. FBW7 phosphorylation status was examined by immunoblot analysis after immunoprecipitation.

    Cell Research, 2015, 25: 561-573. SCH772984 purchased from Selleck.

    K562 cells were exposed to ERK inhibitor SCH772984 (1 uM, 2 uM, 5 uM) for 48 h. Apoptosis was analyzed by Annexin V-APC labeling.

    Leuk Lymphoma 2014 1, 8. SCH772984 purchased from Selleck.

  • ERK1/2 influences the effects of TGF-β1 on Cdk5 and Bax in PC12 cells. A. Original western blot showing the level of Cdk5 and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. B. Arithmetic means ± SEM (n = 4) of Cdk5 protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. C. Original western blot showing the level of Bax and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) for 2 h. D. Arithmetic means ± SEM (n = 4) of Bax protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) for 2 h. **(p < 0.01), ***(p < 0.001) indicate statistically significant difference.

    Biochem Biophys Res Commun, 2017, 485(4):775-781. SCH772984 purchased from Selleck.

产品安全说明书

ERK抑制剂选择性比较

生物活性

产品描述 SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。
特性 SCH772984不直接抑制MEK1, MEK2, BRAF, 或 CRAF酶活性。
靶点
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
体外研究

SCH772984是新型,选择性,ATP竞争性的ERK1/2抑制剂。SCH772984抑制ERK底物p90核糖体S6激酶(T359/S363 磷酸化-RSK)的磷酸化,这种作用存在剂量依赖性。SCH772984也能抑制ERK自身活化环中残基的磷酸化。SCH772984分别抑制约88%和49%BRAF突变型或RAS-突变型肿瘤细胞系,EC50值<500 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 NXS0e|BjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMkSgcm0> M{fkVFI2OzVyOUOx
WM-266-4 M2nX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJyIH7N NXzL[XlFOjN4MUS4PVg>
UACC-62 NWPudpY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF31XFVKSzVyPUOwJI5O M2XsWFI{PjF2OEm4
Colo-205 M{fOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KxTWlEPTB;M{[gcm0> NFXydIwzOzZzNEi5PC=>
SK-Mel-1 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\HRWlEPTB;M{egcm0> M3fx[VI{PjF2OEm4
WiDr MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTN7IH7N M1fvfVI{PjF2OEm4
M14 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG2WlBKSzVyPUS3JI5O NIHifWwzOzZzNEi5PC=>
HT-29 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTVyIH7N Mn:wNlM3OTR6OUi=
8505C NEPTXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfkVZhtUUN3ME21NEBvVQ>? NVf1flhKOjN4MUS4PVg>
HT-144 NUi0S5N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTZyIH7N NF\GS5YzOzZzNEi5PC=>
SK-Mel-5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjwdJFRUUN3ME22OkBvVQ>? MXqyN|YyPDh7OB?=
A375-SM NFrwNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTyTWM2OD15NTDuUS=> NFfsOHIzOzZzNEi5PC=>
SK-Mel-28 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTh3IH7N NULUTW1JOjN4MUS4PVg>
LOX MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFyMDDuUS=> MkfHNlM3OTR6OUi=
SK-Mel-3 NITEbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHiSGJKSzVyPUGxPEBvVQ>? NXWwbmpoOjN4MUS4PVg>
K1 NUD6T2FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\CRmlEPTB;MUOwJI5O MlvVNlM3OTR6OUi=
Hs-695T MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnvTnJRUUN3ME2xOlUhdk1? MlHONlM3OTR6OUi=
BHT-101 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nEPGlEPTB;M{CwJI5O Mn;JNlM3OTR6OUi=
RPMI-7951 NUnHZYJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTN2NDDuUS=> M1jWZVI{PjF2OEm4
A2058 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXNTWM2OD1|NkCgcm0> MUCyN|YyPDh7OB?=
SK-Hep-1 NXnYW45UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLNTWM2OD1zNEKyJI5O MlnpNlM3OTR6OUi=
A673 MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPZZ4NKSzVyPUOwNFEhdk1? MXuyN|YyPDh7OB?=
DBTRG-05MG NFnDO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C4c2lEPTB;M{CwNUBvVQ>? MmPCNlM3OTR6OUi=
SW-626 NVrNPYo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7ZTWM2OD1|MzDuUS=> NXHXZXZNOjN4MUS4PVg>
LoVo NEfvSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT6OVBjUUN3ME20O{BvVQ>? NYfFVop[OjN4MUS4PVg>
MiaPaCa Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn4UGRKSzVyPUWzJI5O NHjRNIkzOzZzNEi5PC=>
SW-620 NW\sbm1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\2TWM2OD1zMESgcm0> Mnj4NlM3OTR6OUi=
CAPAN-1 M1e5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFyNDDuUS=> NXztenFqOjN4MUS4PVg>
SW-527 M{n2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jGXGlEPTB;MUKxJI5O MVmyN|YyPDh7OB?=
HCT-116 NEHsclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLsTWM2OD1zMkigcm0> MVqyN|YyPDh7OB?=
SW-480 NGnhTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XwWmlEPTB;MU[1JI5O MlLHNlM3OTR6OUi=
HPAC Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzPRVljUUN3ME2xO|Ahdk1? NXiwZ4RMOjN4MUS4PVg>
OVCAR-5 NULIRY1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3rRZBKSzVyPUKwPEBvVQ>? NX\3fVA6OjN4MUS4PVg>
AsPc-1 NXHTPHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjQRnd5UUN3ME2yO|Ahdk1? MnmxNlM3OTR6OUi=
A549 NWPyR2hlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN{NjDuUS=> NFPNUmUzOzZzNEi5PC=>
SNU-1 M{jTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\yTWM2OD1|NUSgcm0> MoO1NlM3OTR6OUi=
HOP62 MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu0Uo9KSzVyPU[3OkBvVQ>? Mlz3NlM3OTR6OUi=
H23 NFXnWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;oUYJKSzVyPUGwNFAhdk1? MnTRNlM3OTR6OUi=
MB-231 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf4TWM2OD1zMECwJI5O MYCyN|YyPDh7OB?=
SU.86.86 M{PMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFyMEGgcm0> MontNlM3OTR6OUi=
CFPAC-1 NYrORYptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36xVWlEPTB;MUCwNUBvVQ>? NHmwTG0zOzZzNEi5PC=>
A427 NIPybWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;nXXlKSzVyPUG0N|Mhdk1? NFnCfYIzOzZzNEi5PC=>
MDAH-2774 NWrZPYFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO1cHdqUUN3ME2yOlU4KG6P NWjVcXpIOjN4MUS4PVg>
NCI-H157 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTNyMECgcm0> NVPodVhQOjN4MUS4PVg>
HTB-177 NY\XS3NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XpfWlEPTB;M{CwNEBvVQ>? NGTNOGgzOzZzNEi5PC=>
UM-UC-3 NYnWTnhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTNyMEGgcm0> NVzjNIpQOjN4MUS4PVg>
HCT-8 MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nIc2lEPTB;M{CwNUBvVQ>? M1H6XFI{PjF2OEm4
Panc-1 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3lTWM2OD1|MECxJI5O M1fJU|I{PjF2OEm4
DLD-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT6eGhYUUN3ME2zNFAyKG6P M336elI{PjF2OEm4
HCT-15 M2TSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVywW2lXUUN3ME2zNFAyKG6P NELwc20zOzZzNEi5PC=>
HL-60 NIXiOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK0ToRKSzVyPUOwJI5O NXHYVJFMOjN4MUS4PVg>
SK-Mel-2 NUDIXWw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfmboJuUUN3ME2zOEBvVQ>? NHHzN4QzOzZzNEi5PC=>
RD MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzTNWxDUUN3ME2xNlMhdk1? NGLHVnczOzZzNEi5PC=>
HT-1197 MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPUUFZKSzVyPUOxOkBvVQ>? M1L4T|I{PjF2OEm4
Molt-3 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3mxUmlEPTB;NkCwJI5O NGewVogzOzZzNEi5PC=>
PA-1 NGnoXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlztTWM2OD1zMECxJI5O NEnVd3MzOzZzNEi5PC=>
Molt-4 NFj2fHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfVb5BtUUN3ME2zNFAyKG6P M1LxdlI{PjF2OEm4
NCI-H292 NEfofXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTlyIH7N MnrsNlM3OTR6OUi=
A2780 NH;wN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWniPWhxUUN3ME2xOFMhdk1? M4\PeFI{PjF2OEm4
IGROV-1 M4DGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjnR3VrUUN3ME2xOFYhdk1? M{fM[FI{PjF2OEm4
SK-N-SH Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHIT4tKSzVyPUG1NEBvVQ>? M2fy[|I{PjF2OEm4
N-87 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jlbmlEPTB;M{C3JI5O MVKyN|YyPDh7OB?=
H322 NHX0XmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnQNXloUUN3ME2zNlUhdk1? MX6yN|YyPDh7OB?=
H716 NX;FdoxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD2R5RHUUN3ME2zN|Qhdk1? MXeyN|YyPDh7OB?=
TT MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITufo9KSzVyPUSwOkBvVQ>? NHr2bZozOzZzNEi5PC=>
Caki-1 MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H3UGlEPTB;NEWwJI5O Mk\pNlM3OTR6OUi=
5637 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIKydWdKSzVyPU[xNEBvVQ>? NWHCOVVwOjN4MUS4PVg>
MB-453 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\FVlVmUUN3ME22O|Ihdk1? Ml3zNlM3OTR6OUi=
RT-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf2TWM2OD16MUCgcm0> NUXKSm5jOjN4MUS4PVg>
HOP92 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL5TWM2OD16MkCgcm0> NHey[nczOzZzNEi5PC=>
KG-1 NWnRN3hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTlyMDDuUS=> NWfyUJNQOjN4MUS4PVg>
Hs-294T NVP4XFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDKdlFKSzVyPUm0OUBvVQ>? NVzZPYhkOjN4MUS4PVg>
SF-539 NGHvWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jpeGlEPTB;MUCwNEBvVQ>? NUj0e452OjN4MUS4PVg>
U-251 NHrLbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFyMECgcm0> M3fLWFI{PjF2OEm4
MB-468 NUjMd2puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j3OWlEPTB;MUCwNEBvVQ>? MXyyN|YyPDh7OB?=
HS746T NV7XTnd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHaTWM2OD1zMECwJI5O MWWyN|YyPDh7OB?=
SCABER M1fZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnCTZRGUUN3ME2xNFAxKG6P M{f3XlI{PjF2OEm4
MCF-7 MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DIcGlEPTB;MUCwNUBvVQ>? NH\nU20zOzZzNEi5PC=>
CHL-1 NYD0fINKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHuTWM2OD1zNE[wJI5O NIG1W2QzOzZzNEi5PC=>
U87MG NH75XIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLPdWJFUUN3ME2yNFAxKG6P M2nlVVI{PjF2OEm4
SJCRH30 M1facWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr2PIRHUUN3ME2yNFAzKG6P MYiyN|YyPDh7OB?=
ES-2 NVnRUW5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K4eGlEPTB;Mk[1PUBvVQ>? NI\TOFUzOzZzNEi5PC=>
HT-1376 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjJPXoyUUN3ME2yPFAxKG6P MU[yN|YyPDh7OB?=
A172 MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW5TWM2OD1|MECwJI5O M4HselI{PjF2OEm4
769P MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3no[GlEPTB;M{CwNEBvVQ>? M{jSflI{PjF2OEm4
NCI-H520 NYPlR402T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fTXWlEPTB;M{CwNEBvVQ>? MojwNlM3OTR6OUi=
DU145 NWDtcJVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vae2lEPTB;M{CwNEBvVQ>? M13iRVI{PjF2OEm4
K562 M{XzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4riVGlEPTB;M{CwNEBvVQ>? MWiyN|YyPDh7OB?=
U-937 NX\QOldET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPmeXp7UUN3ME2zNFAxKG6P Mk\MNlM3OTR6OUi=
A204 M3TtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO1TWM2OD1|MECxJI5O NUm4[FFHOjN4MUS4PVg>
DAOY MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNyMEGgcm0> NVq0O|hwOjN4MUS4PVg>
SF-268 Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHGTWM2OD1|MECxJI5O NITG[5UzOzZzNEi5PC=>
SF-295 M{CxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{njfmlEPTB;M{CwNUBvVQ>? MnzoNlM3OTR6OUi=
SNB-19 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTW[2luUUN3ME2zNFAyKG6P NXvVdXV2OjN4MUS4PVg>
SNB-75 M3j5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDieXJlUUN3ME2zNFAyKG6P MojKNlM3OTR6OUi=
U373-MG M3\ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInzN25KSzVyPUOwNFEhdk1? MnmyNlM3OTR6OUi=
786-O M4TEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\1PVVIUUN3ME2zNFAyKG6P MkX5NlM3OTR6OUi=
A498 M3zLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNyMEGgcm0> M4DUSVI{PjF2OEm4
ACHN NETZdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTrTWM2OD1|MECxJI5O Mn\NNlM3OTR6OUi=
EKVX MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rQbmlEPTB;M{CwNUBvVQ>? M4HjR|I{PjF2OEm4
H226 M2\wZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ez[2lEPTB;M{CwNUBvVQ>? MWiyN|YyPDh7OB?=
H522 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfzZ2pKSzVyPUOwNFEhdk1? NUDJUIZxOjN4MUS4PVg>
HeLa NUDnXJRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrEWlQ3UUN3ME2zNFAyKG6P NFrRZlQzOzZzNEi5PC=>
SK-OV-3 Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;vc2JKSzVyPUOwNFEhdk1? NH3yN24zOzZzNEi5PC=>
Ln Cap MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TsT2lEPTB;M{CwNUBvVQ>? M1i1OVI{PjF2OEm4
PC3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\6TWlEPTB;M{CwNUBvVQ>? MlfHNlM3OTR6OUi=
SNU-16 NHzpSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnCTWM2OD1|MECxJI5O MlXLNlM3OTR6OUi=
FTC-133 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:4TWM2OD1|MECxJI5O MV[yN|YyPDh7OB?=
Ro82-W-1 M{Tndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNyMEGgcm0> Ml3ENlM3OTR6OUi=
Daudi MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPh[HpKSzVyPUOwNFEhdk1? M1PmWlI{PjF2OEm4
Jijoye M{\KR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTkTWM2OD1|MECxJI5O M1TkclI{PjF2OEm4
Jurkat M1W1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNyMEGgcm0> NVz4boxROjN4MUS4PVg>
J-82 NEf5b2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnIOVVKSzVyPUOwNFEhdk1? MmiwNlM3OTR6OUi=
TCC-SUP MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfBXJNKSzVyPUOwNFEhdk1? NVG0TJl6OjN4MUS4PVg>
BT-474 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT4T5BKSzVyPUOwNFEhdk1? NIOyOZMzOzZzNEi5PC=>
ZR-75-1 M2m2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr6TWM2OD1|MECxJI5O MXmyN|YyPDh7OB?=

... Click to View More Cell Line Experimental Data

体内研究 SCH772984按耐受剂量处理移植瘤模型,诱导肿瘤衰退。SCH772984作用于抗BRAF或MEK抑制剂的模型,有效抑制MAPK信号和细胞增殖。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

ERK2 IMAP 酶实验:

SCH772984作用于纯化的ERK2或ERK1,按一式两份进行8点稀释曲线。酶添加到实验板中。与化合物温育,然后加入底物肽和ATP溶液中。384孔板中每孔加入14μl稀释的酶(每组反应含0.3ng活性ERK2)。实验板轻轻震荡混合试剂,然后在室温下温育45分钟。加入60μl of IMAP 结合溶液 (IMAP珠在1X结合缓冲液中按1:2200稀释)终止反应。实验板在室温下再温育0.5小时,使磷酸肽与IMAP珠完全结合。然后在 LJL分析仪上读数。
细胞实验:

[1]

+ 展开
  • Cell lines: BRAF突变型或 RAS突变型肿瘤系
  • Concentrations: ~10 μM
  • Incubation Time: 5 天
  • Method:

    在96孔板中进行细胞增殖实验,细胞按每孔 4,000个的密度接种。接种24小时后,使用DMSO处理细胞,9点IC50稀释 (0.001-10 μM) ,DMSO终浓度为1%。使用ViaLight发光试剂盒5天后,测定存活力。细胞系存活力检测中,使用SCH772984处理细胞4天,然后进行CellTiterGlo发光细胞活力检测。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 裸鼠
  • Formulation: --
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
5% DMSO+30% PEG 300+ddH2O
0.6mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 587.67
化学式

C33H33N9O2

CAS号 942183-80-4
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • 回答:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

ERK Signaling Pathway Map

Tags: 购买SCH772984 | SCH772984供应商 | 采购SCH772984 | SCH772984价格 | SCH772984生产 | 订购SCH772984 | SCH772984代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID